ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,702.55
      -0.19%
      US Tech 100
      19,287.60
      -0.24%
      Dow Jones
      42,063.36
      0.09%
      Brent Oil
      74.485
      0.81%
      Bitcoin
      63,988.19
      0.57%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Obagi Medical Products, Inc. (MM) (OMPI) Quote

      Obagi Medical Products, Inc. (MM)

      Obagi Medical Products, Inc. (MM) (OMPI)

      NASDAQ
      23.98
      0.00
      (0.00%)
      Closed September 23 4:00PM
      Delayed by 15 minutes
      0.00
      0.00
      (0.00%)
      After Hours: -
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      23.98
      Bid
      0.00
      Ask
      0.00
      Volume
      -
      0.00 Day's Range 0.00
      0.00 52 Week Range 0.00
      Previous Close
      23.98
      Open
      -
      Last Trade
      Last Trade Time
      Average Volume (3m)
      -
      Financial Volume
      -
      VWAP
      -

      Ask ADVFN Intelligence (AI)

      OMPI Latest News

      More News

      Crestwood to Acquire Oasis Midstream Partners in $1.8 Billion Transaction

      Highly complementary Williston Basin and Delaware Basin assets enhance Crestwood’s competitive positioning in its core growth basins Significantly expands Crestwood’s leading position in the...

      October 26 2021
      Business Wire

      Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.

      Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc. PR Newswire LAVAL, Quebec, April 25, 2013 LAVAL, Quebec, April 25, 2013 /PRNewswire/ -- Valeant...

      April 25 2013
      PR Newswire (US)

      Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its...

      Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc. PR...

      April 24 2013
      PR Newswire (US)

      Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstand...

      Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc. PR...

      April 23 2013
      PR Newswire (US)

      Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisitio...

      Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc. PR Newswire MONTREAL, April 22, 2013...

      April 22 2013
      PR Newswire (US)

      Valeant: The Sole Suitor for Obagi - Analyst Blog

      Valeant Pharmaceuticals’ (VRX) proposed acquisition of Obagi Medical Products, Inc. (OMPI) received a boost with Merz Pharma Group opting out of the race to purchase Obagi. Merz’s...

      April 09 2013
      Zacks

      U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH

      Among the companies with shares expected to actively trade in Monday's session are Lufkin Industries Inc. (LUFK), Obagi Medical Products Inc. (OMPI) and Constellation Brands Inc. (STZ). General...

      April 08 2013
      Dow Jones News

      Merz Pharma Withdraws Offer for Obagi Medical After Valeant's Sweetened Bid

      By Tess Stynes Merz Pharma Group withdrew its roughly $385 million offer to acquire Obagi Medical Products Inc. (OMPI), citing Valeant Pharmaceuticals International Inc.'s (VRX, VRX.T) sweetened...

      April 08 2013
      Dow Jones News

      Merz Pharma Group Withdraws Proposal to Acquire Obagi Medical Products

      Merz Pharma Group Withdraws Proposal to Acquire Obagi Medical Products PR Newswire FRANKFURT, Germany, April 8, 2013 FRANKFURT, Germany, April 8, 2013 /PRNewswire/ -- Merz Pharma Group...

      April 08 2013
      PR Newswire (US)

      Valeant Ups Offer for Obagi - Analyst Blog

      Valeant Pharmaceuticals (VRX) recently announced that the company has increased its offer price to acquire Obagi Medical Products, Inc. (OMPI). As per the new agreement, Valeant increased its...

      April 04 2013
      Zacks
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000CS
      40000000CS
      120000000CS
      260000000CS
      520000000CS
      1560000000CS
      2600000000CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      BNZIBanzai International Inc
      $ 5.645
      (96.01%)
      		61.39M
      ZJYLJin Medical International Ltd
      $ 3.975
      (50.00%)
      		1.24M
      ANEBAnebulo Pharmaceuticals Inc
      $ 2.9001
      (39.43%)
      		78.85k
      XPONExpion360 Inc
      $ 0.081
      (39.18%)
      		1.46B
      AENTAlliance Entertainment Holding Corporation
      $ 2.74
      (34.31%)
      		4.23M
      GSIWGarden Stage Ltd
      $ 1.34
      (-82.89%)
      		26.44M
      CRBPCorbus Pharmaceuticals Holdings Inc
      $ 19.51
      (-62.26%)
      		12.29M
      LGCBLinkage Global Inc
      $ 0.4183
      (-57.70%)
      		2.16M
      BFIBurgerFi International Inc
      $ 0.0855
      (-42.27%)
      		15.05M
      SKYESkye Bioscience Inc
      $ 3.17
      (-42.26%)
      		5.14M
      XPONExpion360 Inc
      $ 0.081
      (39.18%)
      		1.46B
      NVDANVIDIA Corporation
      $ 116.00
      (-1.59%)
      		378.16M
      AAPLApple Inc
      $ 228.20
      (-0.29%)
      		320.24M
      INTCIntel Corporation
      $ 21.84
      (3.31%)
      		261.68M
      VERBVerb Technology Company Inc
      $ 0.0742
      (33.45%)
      		178.65M

      OMPI Discussion

      View Posts
      BooDog BooDog 12 years ago
      Far out. Gives my little guys some hope
      congrats!!
      👍️0
      ospreyeye ospreyeye 12 years ago
      OMPI Chart.......Gapper.......huge move today...............$$$

      👍️0
      Edgenation Edgenation 12 years ago
      Ok just sold because of revenue/inventory numbers. I'll be back someday!
      👍️0
      Edgenation Edgenation 12 years ago
      Haha no, just saying that would be nice! but intermediate to long term there is a good chance. We shall see!
      👍️0
      mlkrborn mlkrborn 12 years ago
      In a week?
      GL
      mlkr
      👍️0
      Edgenation Edgenation 12 years ago
      Just got in today at $14.53. Pretty dead board but the company has great near term potential with a possible buyout still! hopefully this runs to $20 in a week!
      👍️0
      mlkrborn mlkrborn 13 years ago
      Obagi Medical: Addresses response by Obagi Board of Directors to its letter says 'Voce commends Obagi's appointment of strategic advisors, and further welcomes its public commitment that any acquisition offers' (OMPI) 11.87 : The letter stated "On February 10, 2012, Voce sent a letter to the Obagi Board of Directors criticizing the Board's recent adoption of a poison pill and demanding immediate action to address corporate governance deficiencies and to evaluate strategic alternatives. Voce's letter stated that it believed Obagi has spurned recent overtures to acquire the Company. On February 14, 2012, the Obagi Board responded to Voce's letter. The Board's statement notably did not dispute Voce's claims that the Company had recently received and summarily rebuffed offers to acquire Obagi. In addition, the Obagi Board's response states in part: Voce commends Obagi's appointment of strategic advisors, and further welcomes its public commitment that any acquisition offers from this point forward will be reviewed by these independent advisors. Voce believes that this change in Obagi's posture may invite additional acquisition interest....There is substantial strategic interest in an acquisition of Obagi and broad support for a sale of the Company in both the investment and the analyst community. It behooves the Obagi Board to pursue this potential outcome diligently."
      👍️0
      mlkrborn mlkrborn 15 years ago
      Too bad no one covered but up since its creation: Chart!
      http://stockcharts.com/h-sc/ui?s=ompi&p=D&yr=0&mn=6&dy=0&id=p97690170109
      👍️0
      kmx_swing kmx_swing 16 years ago
      OMPI board created
      👍️0

      Your Recent History

      NASDAQ
      OMPI
      Delayed Upgrade Clock